Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Name: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Published: 2025
License: Public Domain

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

paclitaxel

recurrent / metastatic head and neck squamous cell carcinoma, squamous cell carcinoma of the head and neck, scchn, cetuximab, paclitaxel, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Related documents